Results 221 to 230 of about 88,264 (269)

Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL/SLL: A pooled analysis of ibrutinib trials. [PDF]

Ther Adv Hematol
Abuhelwa AY, Almansour SA, Al-Shamsi HO, Abuhelwa Z, Ziade MA, Bustanji Y, Semreen MH, Alqudah MAY, McKinnon RA, Alzoubi KH, Sorich MJ, Hopkins AM.   +11 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort. [PDF]

Br J Haematol
Katsimigas A, Werling M, Frederiksen CM, Vainer N, Rostgaard K, Ben-Dali Y, Hleuhel MH, Brieghel C, Niemann CU, da Cunha-Bang C.   +9 more
europepmc   +1 more source

Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eµ-TCL1 mice. [PDF]

Front Oncol
Skupa SA, Hernandez JB, Smith AL, Drengler EM, Rai J, Pan J, Seth AK, Rai SN, Clayton JB, D'Angelo CR, El-Gamal D.   +10 more
europepmc   +1 more source

Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report. [PDF]

Front Cardiovasc Med
Wang H, Zhu F, Hu H.
europepmc   +1 more source

Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T-Cell Therapy in TP53-Deleted CLL: A Case Report. [PDF]

EJHaem
Alfraih F, Saleh MFM, Li D, Mohty R, Kharfan-Dabaja M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CLL immunotoxins

Leukemia Research, 2005
Immunotoxins composed of cell-selective ligands covalently linked to peptide toxins have been developed for the treatment of chemotherapy relapsed or refractory malignancies including chronic lymphocytic leukemia (CLL). A number of CLL immunotoxins have been clinically tested including T101-ricin A, H65-ricin A, DAB(486)IL2, DAB(389)IL2, RFB4 (dsFv ...
Arthur E, Frankel, Robert J, Kreitman
openaire   +2 more sources

Molecular basis of CLL [PDF]

Seminars in Cancer Biology, 2010
B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world, results from an expansion of a rare population of CD5+ mature B-lymphocytes. CLL occurs in two forms, aggressive and indolent. For the most part indolent CLL is characterized by low ZAP-70 expression and mutated IgH V(H); aggressive CLL shows high ZAP-70 ...
Carlo Maria Croce, Yuri Pekarsky, Nicola Zanesi   +2 more
exaly   +3 more sources

CLL

Oncology Times, 2014
  +9 more sources

Immunotherapies in CLL

2013
Chronic lymphocytic leukemia (CLL) is the most frequently diagnosed leukemia in the Western world, yet remains essentially incurable. Although initial chemotherapy response rates are high, patients invariably relapse and subsequently develop resistance to chemotherapy.
Jae H, Park, Renier J, Brentjens
openaire   +2 more sources

Maintenance in CLL

Blood, 2013
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).
openaire   +2 more sources